# Sleep Duration and the Risk of Metabolic Syndrome: a Systematic Review and Meta-analysis

- 1 Jianian Hua<sup>13,#</sup>, Hezi Jiang<sup>23,#</sup>, Qi Fang<sup>1,\*</sup>
- <sup>2</sup> <sup>1</sup> Department of Neurology, The First Affiliated Hospital of Soochow University, Suzhou, 215006,
- 3 Jiangsu Province, China.
- <sup>4</sup> <sup>2</sup> Department of Cardiology, The First Affiliated Hospital of Soochow University, Suzhou, China.
- <sup>5</sup> <sup>3</sup> Medical College of Soochow University, Suzhou 215123, PR China.
- 6 <sup>#</sup>These authors contributed equally.
- 7 \*Corresponding author
- 8 Qi Fang
- 9 fangqi\_008@126.com

#### Abstract

- Objective: Epidemiologic studies have reported inconsistent findings about the association between
- sleep duration and metabolic syndrome. We aimed to clarify this association by method of meta-
- analysis.
- Methods: Medline, Embase, CINAHL and PsycINFO databases were searched from inception to
- May 2020. We collected data from 235,895 participants from 9 prospective cohort studies, and
- 340,492 participants from 26 cross-sectional studies. Risk ratios (RR) or odds ratios (OR) were
- calculated separately for cohort studies and cross-sectional studies, through meta-analysis of adjusted
- data from individual studies.
- Results: For cohort studies, short sleep duration was associated with an increased risk of metabolic
- syndrome (RR, 1.15; 95% CI, 1.05-1.25). Long sleep duration was not associated with new onset
- metabolic syndrome (RR, 1.02, 0.85-1.18). For cross-sectional studies, both short (OR, 1.12, 95% CI,
- 1.08-1.18) and long (OR, 1.06, 1.01-1.11) sleep duration was associated with high prevalence of
- metabolic syndrome.
- Conclusions: Only short sleep duration was associated with an increased risk of metabolic syndrome.
- Future studies should address whether the association is casual and modifiable.
- **Keywords:** sleep duration, metabolic syndrome, cohort study, meta-regression, meta-analysis

#### 71 **1** Introduction

Metabolic syndrome is a cluster of disorders that occur together, and it is defined as a condition consisting of at least three of the following: hypertension, high blood sugar, excessive waist circumference, higher triglyceride (TG) levels or low high-density cholesterol (HDL) levels. Metabolic syndrome is associated with adverse cardiovascular events, even after adjusted for diabetes and obesity<sup>1,2</sup>. Meanwhile, the prevalence of metabolic syndrome in America is up to 33%<sup>3</sup>. Recently,

- 77 growing concern has been paid to the modifiable risk factors of metabolic syndrome<sup>4</sup>.
- Abnormal sleep duration is known to increase the risk of a serious health outcomes, including mortality, diabetes and cardiovascular disease<sup>5,6</sup>. Therefore, both sleep and metabolic syndrome increase the risk of cardiovascular event. However, whether abnormal sleep duration increase the risk of metabolic syndrome remained controversial. Several meta-analyses have reported the association between sleep duration and metabolic syndrome<sup>7-9</sup>. However, none of the studies assessed the association in a prospective cohort design, which has less substantial bias could provide stronger
- 84 support for causality<sup>6,10,11</sup>.

85 Therefore, we conducted a systemic review and meta-analysis to: (1) examine all prospective cohort

86 studies that have assessed the effect of sleep duration on the future risk of metabolic syndrome; (2)

87 conduct an updated meta-analysis to examine the cross-sectional association.

#### 88 2 Materials and Methods

We performed this study according to Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines (Table S1).

91 Two independent researchers (JNH and HZJ) separately assessed the eligibility, extracted data, and

92 checked the quality of the included studies. Any disagreement in screening the articles were resolved

93 through discussion between these two, with adjudication by a third research (QF) if disagreements

94 persisted.

#### 95 2.1 Search strategy

96 A systematic search was conducted in Medline, Embase, CINAHL and PsycINFO from inception to

97 May 2020. We used the following search terms: (1) "sleep hour" OR "sleeping hour" OR "hours of

sleep" OR "sleep duration" OR "sleep time" OR "sleep length" OR "sleep period" OR "sleeping time"

99 OR "sleep span"; (2)"metabolic syndrome" or "MetS" or "MS" or "syndrome X" or "cardiometabolic

risk factor" or "insulin resistance syndrome". Algorithms combining the two sets of search termswere applied.

#### 102 2.2 Study selection

Studies that examined the relationship between sleep duration and metabolic syndrome were screened for eligibility, without language restriction. The inclusion criteria were: (1) the research was a cohort or a cross-sectional study; (2) the research compared individuals with "unnormal" and "normal" sleep duration on the outcome of metabolic syndrome. If one or more articles reported data from one study, the article with the largest sample size and the best design was included.

We analyzed cohort studies and cross-sectional studies separately in all analysis due to the following reasons. First, cross-sectional study could not establish a causal relationship, and it only reflected the association between sleep duration and the prevalence of metabolic syndrome<sup>11</sup>. Second, the nonexposed prevalence of metabolic syndrome was higher than  $20\%^{12}$ , odds ratios (OR) could not be regarded as risk ratio (RR)<sup>13</sup>.

113 The inclusion of studies was conducted in two stages: (1) screening of the title and abstract and (2) 114 screening of the full text.

#### 115 **2.3 Data extraction**

The following characteristics were extracted from each eligible study: author name and publication year, study type, study location (country and continent), sample size, participants' characteristics (age range, mean age and sex composition), exposure and outcome assessment (sleep assessment, metabolic syndrome measures and definition of long or short sleep duration) and main results.

120 Since definition of sleep duration varies among studies<sup>14</sup>, the three categories of sleep duration (short,

121 long and normal) was extracted by one of the following two ways. For some papers, sleep duration 122 was already divided into three categories based on cultures and ethnicities. For others, in which sleep 123 duration was divided into more than three groups, short or long sleep duration was defined as the 124 shortest or longest group reported in the article<sup>6</sup>. With regard to the main results, the adjusted 125 estimates that reflected the most comprehensive control were extracted.

Data were extracted by two investigators (JNH and HZJ) independently. Disagreement in screening the articles was resolved by discussion between the two investigators. Consultation from a third investigator (QF) was acquired if necessary.

#### 129 **2.4 Exposure and outcome measures**

130 With regard to the measurements of nocturnal sleep duration, two studies used objective131 measurement, while others used interview or questionnaire.

132 The diagnostic criteria of metabolic syndrome (MetS) varied between studies. 10 studies used the 133 Third Report of the National Cholesterol Education Program's Adult Treatment Panel III (NECP 134 ATP-III); 4 studies used modified NECP ATP-III; 14 studies used the American Heart 135 Association/National Heart Lung and Blood Institute (AHA-NHLBI); 3 studies used the International

136 Diabetes Federation  $(IDF)^8$ ; 5 studies used other criteria.

#### 138 **2.5 Quality appraisal**

139 The quality of all studies was evaluated by Newcastle-Ottawa Quality Assessment Scale  $(NOS)^{15}$ .

140 The total score ranged from 0-9 scores. For outcome category and comparability category, all the

studies had similar quality. The difference between studies lied in the study design category (TableS3).

143 **2.6 Data analysis** 

144 We conducted all the following analysis separately for cohort studies and cross-sectional studies, and 145 for study-specific short and long sleep duration, respectively.

146 In analysis of cohort studies, hazard ratios (HRs) were regarded as risk ratios (RRs). For studies

147 which provided only odds ratios (ORs), we calculated RRs by using the ORs and control event rates

148 (CERs) in normal sleepers. Using random-effect models, we estimated the pooled RR and 95% CI.

- With regard to cross-sectional studies, we calculated the pooled OR and 95%CI using random-effect models.
- Heterogeneity between the studies was assessed using Cochran Q statistics (P<0.1 indicates statistically significant heterogeneity) and  $I^2$  statistic ( $I^2$ >50% indicates statistically significant heterogeneity)<sup>16</sup>. To examine publication bias, we used a funnel plot, the Egger regression test, and the Begg and Mazumdar test<sup>17,18</sup>. "Trim and fill" method was used to adjust the funnel plot, and recalculated the results<sup>19,20</sup>. Sensitivity analysis was performed by excluding one study at a time to

156 test the robustness of the pooled estimates.

Subgroup analysis was conducted to explore the potential heterogeneity among cross-sectional studies. We used z test to compare summary estimates of each subgroups<sup>21</sup>. Univariate and multivariate meta-regression were used to study the effect of possible influential confounders, such as definition of sleep duration and study quality. For cohort studies, subgroup analysis and metaregression was not performed considering the small number of datasets included in the meta-analysis.

162 All statistical analysis was performed by R-3.4.3<sup>20</sup> and Stata 15.1 (Stata Corp, College Station, TX).

163 **3 Results** 

### 164 **3.1 Search results**

165 The initial electronic search yielded 1140 articles, among which 789 were reviewed by title and 166 abstract. 127 full-texts were retrieved. 35 studies were included in the final analysis (Figure 1).

#### 167 **3.2** Characteristics of study samples

168 We identified nine prospective cohort studies that examined the association between sleep duration

and the incident risk of metabolic syndrome, in a total of 235,895 participants. The sample size

170 ranged from 293 to 162,121. The mean follow-up duration ranged from 2 to 8 years (Table 1).

- 171 Another twenty-six studies were cross-sectional studies, included a total of 340,492 individuals. The
- 172 sample size ranged from 263 to 88,678 (Table S2).
- 173 Table 1 and Table S2 presented the characteristics of the all 35 studies. The individuals all aged
- above 18 year. The mean (SD) age of the individuals ranged from 31 (8.7) to 67.6 (7.3) years. The
- 175 studies were conducted in five continents, while many of them were from Asia. The definitions of
- 176 short or long sleep duration varied between studies. About 75% studies defined "short sleep duration"
- 177 as < 6 or < 7 h, and about 80% studies defined "long sleep duration" as > 8 or > 9 h.

#### 178 **3.3 Primary analysis**

#### 179 **3.3.1 Sleep duration and the risk of metabolic syndrome**

- 180 Compared with moderate sleep duration, short sleep duration was associated with a statistically
- 181 significant increase in new onset metabolic syndrome, with an RR of 1.15 (95% CI=1.05-1.25,
- 182 P<0.001, I<sup>2</sup>=63.6%, N of datasets=11; Figure 2A).
- 183 Compared with moderate sleep duration, the association between long sleep duration and risk of
- 184 metabolic syndrome was not statistically significant, with an RR of 1.02 (95% CI=0.85-1.18,
- 185 P=0.491,  $I^2$ =38.0%, N=9; Figure 2B), using random effect model. The RR reduced to 0.94 (95%
- 186 CI=0.89-0.99, P=0.050,  $I^2$ =38.0%, N=9), using fixed effect model.
- 187 Among the seven studies that examined the effect of long sleep duration, six did not observe a 188 significant association. Only Li X. found that long sleep duration increased the risk of metabolic
- 189 syndrome among men (adjusted HR=1.96, 95% CI=1.35-2.85).

### 190 **3.3.2 Sleep duration and the prevalence of metabolic syndrome**

- 191 Compared with moderate sleepers, people with short or long sleep duration had a higher prevalence 192 of metabolic syndrome. The pooled OR of metabolic syndrome in short sleepers compared to 193 moderate sleepers was 1.06 (95% CI=1.01-1.11, P<0.001, I<sup>2</sup>=66.5%, N=32; Figure 3A). The pooled 194 OR of metabolic syndrome in long sleepers compared to moderate sleepers was 1.11 (95% CI=1.04-105 1.17, D <0.001, I<sup>2</sup> 72, 8% N = 31; Figure 3P)
- 195 1.17, P<0.001,  $I^2$ =73.8%, N=31; Figure 3B).

# **3.4 Possible publication bias for primary analysis**

Results of Begg and Mazumdar and Egger test were shown in Table S4. No significant publication
bias was observed. "Trim and fill" test indicated that the primary results was still significant after the
missing studies were filled in (Table S5). Visual inspection of the funnel plots also did not reveal
apparent publication bias (Figures not shown).

# 201 **3.5 Subgroup analysis**

202 Subgroup analysis of the cross-sectional studies were shown in Table 2. No significant subgroup 203 difference was found for gender, continent, and definition of abnormal sleep duration. There were 204 statistically significant subgroup effects (P<0.05 for heterogeneity between groups). For short 205 sleepers, the specific domains were study population, sleep measurement, measures of metabolic 206 syndrome and sample size. For long sleepers, the specific domains were sleep measurement, long 207 sleep duration, measures of metabolic syndrome, sample size, and study quality. However, there was 208 still unexplained heterogeneity within some subgroups. Therefore, the subgroup couldn't fully 209 explain the overall heterogeneity.

- For short sleepers, hospital-based participants had a higher OR than the community-based. With regard to definition of short sleep duration, there was a tendency that lower duration was associated with higher OR. Nevertheless, the P value was not significant.
- 213 For long sleepers, compared with "NECP" group, "modified-NECP" group had higher OR. Studies
- with more participants or higher quality had lower OR.

#### 215 **3.6 Sensitivity analysis**

None of the sensitivity analysis substantially altered the effect of both long and short sleep durationon metabolic syndrome (Figure S1).

#### 218 **3.7 Meta-regression**

With regard to cross-sectional studies, a multivariate meta-regression analysis (Table 3) was conducted to examine the potential influence of different factors on the natural logarithm of the OR of short or long sleep duration with prevalence of MetS. For short sleepers, shorter definition of duration was associated with higher OR (P=0.011 for multivariable test, and P=0.099 for univariable test). Higher study quality was associated with lower OR (P=0.010 for univariable test and P=0.033 for multivariable test). The effect of mean age was significant. However, the clinical effect (coef=-0.01) was little. For long sleepers, none of the study factors was significant.

### 226 **4 Discussion**

To our knowledge, this was the first meta-analysis on the association between sleep duration and the risk of metabolic syndrome. Our study indicated that short sleep duration correlated with an increase in the risk of metabolic syndrome. Long duration was not statistically associated with the risk of metabolic syndrome. With regard to cross-sectional studies, both short and long sleep duration was associated with higher prevalence of metabolic syndrome.

Our results differed from that of three previous meta-analysis, which reported the association between sleep duration and metabolic syndrome. Limited by sample size, the three studies did not distinguish cross-sectional studies and cohort studies in the main outcome. *Ju 2013* and *Iftikhar 2015* reported only short sleep duration was associated with metabolic syndrome<sup>7,8</sup>, while *Xi 2014* linked

both short and long sleep duration to metabolic syndrome<sup>9</sup>. Moreover, we observed narrower confidence intervals, which might be due to our higher number of included datasets. Nowadays, a growing number of articles reported an inverted-U shaped association between sleep duration and health outcomes, including metabolic syndrome<sup>22</sup>. Our findings suggested that long sleep duration might have no effect.

241 Compared with the previous studies, we further conducted comprehensive sub-group analysis and 242 meta-regression for cross-sectional studies. In subgroup analysis, using z test, we found no 243 statistically significant differences in subgroups of sex, continent, and sleep measurement. For short 244 sleepers, hospital-based participants had a higher prevalence than community-based participants, 245 which was consistent with a previous meta-analysis. One possible reason was that people in hospital 246 had poor health conditions. The results of subgroup analysis and meta-regression showed that studies 247 with high quality or larger sample size had smaller risk estimates. In multivariable meta-regression, 248 shorter sleep duration was linearly associated with higher prevalence of metabolic syndrome. Longer 249 sleep duration had no linear association. This "J-shaped" association was not consistent with the "Ushaped" association between sleep duration reported in many articles<sup>22</sup>. However, we thought this 250 was not contradictory. In the meta-regression, "sleep duration" was a cut-off point defined by 251 252 different authors from different ethnicities; and in one specific study, the author calculated the 253 association among participants from a same ethnic.

254 Several mechanisms linked sleep duration to metabolic syndrome. Short sleep duration could lead to 255 the following endocrine changes, by affecting carbohydrate metabolism, hypothalamo-pituitary-256 adrenal axis and sympathetic activity. Decreased glucose tolerance and insulin sensitivity would raise 257 the glucose levels; increased levels of ghrelin, decreased levels of leptin and increased appetite 258 correlated with higher waist circumstance; increased cortisol concentrations were associated with higher blood pressure<sup>23,24</sup>. Short sleepers tended to have low-grade inflammation. Elevated levels of 259 high-sensitivity C-reactive protein and IL-6 correlated with cardiovascular events<sup>25</sup>. Long sleep 260 261 duration was linked to sleep fragmentation, which would cause plenty of health outcomes, including metabolic change<sup>26</sup>. Long sleepers also have less time to take excise, which might contribute to the 262 association<sup>27</sup>. Both short and long sleep duration had bidirectional association with circadian rhythm, 263 which is a risk factor for metabolic disorders<sup>28,29</sup>. Despite these mechanisms which could explain the 264 association, whether sleep duration was a causal risk factor for metabolic syndrome was still not 265 sure<sup>30</sup>. Cohort studies still could not provide a causal result, though they have more power than cross-266 267 sectional studies. To prove a causal relationship, we need further examine the effect of changes in sleep duration<sup>31</sup>, and product Mendelian randomization study, a method using measured variation in 268 269 genes.

Our meta-analysis summarized the currently evidence of the association between abnormal sleep duration and the risk of metabolic syndrome, and indicated that short sleep duration was a risk factor for new onset metabolic syndrome. Strength of our study were the comprehensive search and strict inclusion criteria. However, there were some limitations that should be taken into consideration. First,

the sleep categories varied between studies. There was no unified standard for definition of abnormal sleep duration. Second, the estimates of relative risk had less accuracy than that in the individual patient data meta-analysis. Third, we only included nine cohort studies, which prevent us from conducting further research, such as subgroup analysis and meta-regression. Fourth, only two studies used objective sleep measurement. More studies based on the objective measurement are needed in the future.

#### 280 **5** Conclusions

Both short and long sleep duration was associated with high prevalence of metabolic syndrome crosssectionally. Short sleep duration, rather than long sleep duration, was associated with a significant increase in risk for metabolic syndrome. Sufficient sleep duration should be recommended to prevent metabolic syndrome.

285

#### 286 **6** Author contributions

Qi Fang and Jianian Hua contributed to the conception and design of the study. Jianian Hua organized the database. Jianian Hua and Hezi Jiang performed the statistical analysis. Jianian Hua wrote the first draft of the manuscript. Qi Fang and Hezi Jiang reviewed the manuscript. All authors approved the final version of the paper.

#### 291 **7 Funding**

292 This study was not supported by any funding.

#### **293 8 Conflicts of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**296 9 Preprint** 

#### 297 **10 Tables**

#### 298 10.1 Table 1. Characteristics of cohort studies

Author, Year	Study type	Country,	Sample	Mean age $\pm$	Male%	Study population	n	Sleep	Metabolic	Sleep	Main findings reported
	(follow-up	Continent	size	SD, range				meausrement	syndrome	(h)	in original article
	time)								measurement		Adjusted
											HR/RR/OR (95% CI)
Choi, 2011	Cohort	Korea	2093	40-55	0	Community		Interview	NECP ATP-III	<6	aHR 1.80(1.06-3.05)
(male) <sup>32</sup>	(2-4)	Asia								6-8	Ref.
										<u>≥</u> 10	aHR 1.57(0.61-4.01)
Choi, 2011	Cohort	Korea	2133	40-55	100	Community		Interview	NECP ATP-III	<6	aHR 0.62(0.24-1.64)
(female)32	(2-4)	Asia								6-8	Ref.
										<u>≥</u> 10	aHR 1.66(0.71-3.88)
Otsuka,	Cohort	Japan	2090	44.6	47.2	Community		Questionnaire	Japanese criteria	<u>≤</u> 5	aHR 3.18 (1.52-6.64)
201133	(3.7)	Asia		35-63						>6	Ref.
Chaput,	Cohort	Canada	293	39.2±14.3	NA	Community		Questionnaire	AHA-NHLBI	<u>≤</u> 6	aHR 1.82(1.16-4.79)
2013 <sup>34</sup>	(6)	North America		18-65						7-8	Ref.
										<u>≥</u> 9	aHR 1.13(0.58-1.98)
Kim, 2015 <sup>35</sup>	Cohort	Korea	2579	54.1±8.3	34.5	Company	or	Interview	AHA-NHLBI	<6	aOR 1.41(1.06-1.88)
	(2.6)	Asia		≥20		office				7-8	Ref.
										≥10	aOR 0.68 (0.39-1.17)
Li, 2015	Cohort	China	4774 for all	30-65	100	Community		Questionnaire	AHA-NHLBI	<6	aRR 1.87 (1.51-2.30)
(male) <sup>36</sup>	(4.4)	Asia				-		-		7-8	Ref.
										>8	aRR 1.96 (1.35-2.85)
Li, 2015	Cohort	China	4774 for all	30-65	0	Community		Questionnaire	AHA-NHLBI	<6	aRR 0.93 (0.73-1.19)
(female)36	(4.4)	Asia				2		-		7-8	Ref.
										>8	aRR 0.93 (0.60-1.53)
Song, 2016 <sup>37</sup>	Cohort	China	11661	47.0±12.0	82.1	Hospital		Questionnaire	AHA-NHLBI	<u>≤</u> 5.5	aHR 1.22 (1.00-1.49)
0	(2)	Asia		18-98				-		7	Ref.
										<u>≥</u> 8.5	aHR 1.24 (0.93-1.66)
Deng, 2017 <sup>12</sup>	Cohort	Taiwan	162121	20-80	47.4	Community		Questionnaire	AHA-NHLBI	<6	aHR 1.09 (1.05-1.13)
-	(8)	Asia				-		-		6-8	Ref.
	. ,									>8	aHR 0.93 (0.88-0.99)
Itani, 2017 <sup>38</sup>	Cohort	Japan	39182	42.4±9.8	100	Company	or	Questionnaire	Japanese criteria	<5	aHR 1.08 (1.03-1.14)
,	(7)	Asia		≥20		office			L .	≥5	Ref.
Yingnan,	Cohort	China	8969	56.7±7.7	35	Community		Questionnaire	Chinese Criteria	<6	aOR 1.25(0.75 2.08)
2020 <sup>39</sup>	(3)	Asia		35-75						7-8	Ref.
-	. /									>9	aOR 0.96 (0.69,1.33)

#### **10.2 Table 2. Subgroup meta-analysis of cross-sectional studies**

#### 

	Short sleep					Long sleep				
	No.	OR (95% CI)	$I^2$	$P_z^{a}$	No.	OR (95% CI)	$I^2$	$P_z$		
Gender										
Men	7	1.05 (0.98, 1.12)	46.0	Ref.	7	1.03 (0.99, 1.08)	14.0	Ref.		
Women	7	0.99 (0.89, 1.09)	56.8	0.121	7	1.09 (1.00, 1.18)	67.9	0.272		
		P=0.174 <sup>b</sup>				P=0.104				
Continent										
Asia	19	1.08 (1.01, 1.17)	75.8	Ref.	20	1.12 (1.05, 1.20)	79.0	Ref.		
Europe	6	1.03 (0.98, 1.08)	20.8	0.271	6	1.17 (1.01, 1.36)	64.6	0.58		
North Europe	5	1.31 (0.99, 1.74)	24.5	0.205	4	1.22 (0.75, 2.00)	15.0	0.736		
South Europe	1	1.70 (1.19, 2.44)	0.0	0.016	1	1.08 (0.92, 4.26)	0.0	0.147		
Africa	1	0.96 (0.51, 1.81)	0.0	0.708		P=0.171				
		P=0.173								
Study population										
Community	21	1.03 (0.98, 1.08)	57.7	Ref.	22	1.14 (1.07, 1.21)	65.9	Ref.		
Hospital	5	1.36 (1.21, 1.53)	45.7	< 0.001	5	1.10 (0.77, 1.59)	91.6	0.885		
Company or office	6	1.15 (0.93, 1.41)	37.6	0.334	4	1.09 (0.93, 1.28)	0.0	0.64		
		P<0.001				P=0.261				
Sleep measurement										
Questionnaire	16	1.08 (0.99 ,1.18)	69.4	Ref.	15	1.11 (1.03, 1.20)	87.6	Ref.		
Interview	8	1.13 (1.04, 1.23)	76.3	0.496	8	1.12 (1.01, 1.24)	36.6	0.89		
Standard questionnaire	6	1.02 (0.92, 1.13)	0.0	0.363	6	1.13 (0.90, 1.40)	81.1	0.94		
Objective	2	0.92 (0.67, 1.28)	0.0	0.349	2	1.27 (0.63, 2.56)	28.3	0.73		
		P=0.012				P=0.021				
Definition of sleep duration										
< 5 for short or 9 for long	5	1.23 (0.98, 1.5)	29.2	Ref.	7	1.09 (0.92, 1.29)	67.3	Ref.		
< 6 for short or for long	13	1.13 (1.02, 1.24)	82.4	0.492	17	1.18 (1.09, 1.27)	53.6	0.405		
< 7 for short or for long	2	1.04 (0.98, 1.11)	20.4	0.164	6	1.01 (0.92, 1.11)	93.0	0.464		
< 8	2	0.98 (0.90, 1.06)	0.0	0.065		P=0.121				
		P=0.154								
MetS measurement										
NECP ATP-III	12	1.06 (0.98, 1.16)	68.2	Ref.	10	1.07 (0.98, 1.15)	73.8	Ref.		
Modified NECP ATP-III	6	1.00 (0.94, 1.07)	34.3	0.308	6	1.22 (1.15, 1.28)	35.8	0.00		
AHA-NHLBI	9	1.20 (1.03, 1.39)	44.3	0.186	9	1.23 (1.01, 1.50)	27.3	0.19		
IDF	3	1.05 (0.88, 1.25)	21.0	0.879	5	1.07 (1.01, 1.14)	33.4	0.94		
Others	2	1.40 (1.22, 1.61)	14.1	< 0.001	1	0.98 (0.81, 1.19)	10.1	0.42		
		P<0.001				P<0.001				

#### 304 Table 2-Continued Subgroup meta-analysis of cross-sectional studies

	Short sleep					Long sleep				
	No.	OR (95% CI)	I <sup>2</sup>	Pz	No.	OR (95% CI)	I <sup>2</sup>	Pz		
Sample size										
<5000	23	1.07 (0.99, 1.06)	49.7	Ref.	18	1.28 (1.12, 1.47)	56.2	Ref.		
5000-20000	5	1.09 (0.96, 1.25)	57.4	0.842	8	1.05 (0.95, 1.15)	82.0	0.018		
>20000	4	1.11 (1.00, 1.23)	51.3	0.638	5	1.09 (1.01, 1.18)	82.1	0.044		
		P=0.004				P<0.001				
Study quality										
High	7	1.03 (1.00, 1.06)	26.9	Ref.	7	1.03 (0.97, 1.09)	60.5	Ref.		
Low	25	1.06 (1.03, 1.09)	63.4	0.013	23	1.15 (1.06, 1.25)	70.7	0.03		
		P=0.143				P<0.001				

# **10.3 Table 3. Results of meta-regression analysis of cross-sectional studies**

Mean age, years $-0.01 (-0.02, -0.01)$ $0.020$ $-0.01 (-0.01, 0.00)$ $0.086$ Proportion of males, % $0.08 (-0.10, 0.27)$ $0.356$ $-0.05 (-0.23, 0.14)$ $0.622$ Definition of short/long sleep $-0.07 (-0.15, 0.01)$ $0.099$ $-0.08 (-0.15, -0.12)$ $0.011$ Sample size $0.01 (-0.08, 0.09)$ $0.864$ $0.01 (-0.09, 0.09)$ $0.351$ Study quality $-0.15 (-0.30, 0.00)$ $0.039$ $-0.26 (-0.61, 0.09)$ $0.149$ Long sleep durationUnivariable analysisCoef.P valueCoef.P valueMean age, years $0.00 (0.00, 0.01)$ $0.113$ $0.00 (-0.00, 0.01)$ $0.720$ Proportion of males, % $0.01 (-0.18, 0.02)$ $0.891$ $-0.04 (-0.44, 0.35)$ $0.828$ Definition of short/long sleep $-0.16 (-0.33, 0.10)$ $0.776$ $-0.09 (-0.28, 0.10)$ $0.958$ Sample size $-0.09 (-0.18, 0.00)$ $0.056$ $-0.08 (-0.25, 0.08)$ $0.318$				p duration			
Mean age, years $-0.01 (-0.02, -0.01)$ $0.020$ $-0.01 (-0.01, 0.00)$ $0.086$ Proportion of males, % $0.08 (-0.10, 0.27)$ $0.356$ $-0.05 (-0.23, 0.14)$ $0.622$ Definition of short/long sleep $-0.07 (-0.15, 0.01)$ $0.099$ $-0.08 (-0.15, -0.12)$ $0.011$ Sample size $0.01 (-0.08, 0.09)$ $0.864$ $0.01 (-0.09, 0.09)$ $0.351$ Study quality $-0.15 (-0.30, 0.00)$ $0.039$ $-0.26 (-0.61, 0.09)$ $0.149$ Long sleep durationUnivariable analysisCoef.P valueCoef.P valueMean age, years $0.00 (0.00, 0.01)$ $0.113$ $0.00 (-0.00, 0.01)$ $0.720$ Proportion of males, % $0.01 (-0.18, 0.02)$ $0.891$ $-0.04 (-0.44, 0.35)$ $0.828$ Definition of short/long sleep $-0.16 (-0.33, 0.10)$ $0.776$ $-0.09 (-0.28, 0.10)$ $0.958$ Sample size $-0.09 (-0.18, 0.00)$ $0.056$ $-0.08 (-0.25, 0.08)$ $0.318$		Univariable analysis	5	•			
Proportion of males, % $0.08 (-0.10, 0.27)$ $0.356$ $-0.05 (-0.23, 0.14)$ $0.622$ Definition of short/long sleep $-0.07 (-0.15, 0.01)$ $0.099$ $-0.08 (-0.15, -0.12)$ $0.011$ Sample size $0.01 (-0.08, 0.09)$ $0.864$ $0.01 (-0.09, 0.09)$ $0.351$ Study quality $-0.15 (-0.30, 0.00)$ $0.039$ $-0.26 (-0.61, 0.09)$ $0.149$ Long sleep durationUnivariable analysisCoef.P valueCoef.P valueCoef.P valueProportion of males, % $0.01 (-0.18, 0.02)$ $0.891$ $-0.04 (-0.44, 0.35)$ $0.828$ Definition of short/long sleep $-0.16 (-0.33, 0.10)$ $0.776$ $-0.09 (-0.28, 0.10)$ $0.958$ Sample size		Coef.	P value	Coef.	P valu		
Definition of short/long sleep $-0.07 (-0.15, 0.01)$ $0.099$ $-0.08 (-0.15, -0.12)$ $0.011$ Sample size $0.01 (-0.08, 0.09)$ $0.864$ $0.01 (-0.09, 0.09)$ $0.351$ Study quality $-0.15 (-0.30, 0.00)$ $0.039$ $-0.26 (-0.61, 0.09)$ $0.149$ Long sleep durationUnivariable analysisCoef.P valueCoef.P valueCoef.P valueCoef.P valueProportion of males, % $0.01 (-0.18, 0.02)$ $0.891$ $-0.04 (-0.44, 0.35)$ $0.828$ Definition of short/long sleep $-0.09 (-0.18, 0.00)$ $0.056$ $-0.08 (-0.25, 0.08)$ $0.318$	Mean age, years	-0.01 (-0.02, -0.01)	0.020	-0.01 (-0.01, 0.00)	0.086		
Sample size $0.01 (-0.08, 0.09)$ $0.864$ $0.01 (-0.09, 0.09)$ $0.351$ Study quality $-0.15 (-0.30, 0.00)$ $0.039$ $-0.26 (-0.61, 0.09)$ $0.149$ Long sleep durationUnivariable analysisCoef.P valueCoef.P valueCoef.P valueCoef.P valueProportion of males, % $0.01 (-0.18, 0.02)$ $0.891$ $-0.04 (-0.44, 0.35)$ $0.828$ Definition of short/long sleep $-0.09 (-0.18, 0.00)$ $0.056$ $-0.08 (-0.25, 0.08)$ $0.318$	Proportion of males, %	0.08 (-0.10, 0.27)	0.356	-0.05 (-0.23, 0.14)	0.622		
Study quality       -0.15 (-0.30, 0.00)       0.039       -0.26 (-0.61, 0.09)       0.149         Long sleep duration         Univariable analysis         Coef.       P value       Coef.       P value         Multivariable analysis         Coef.       P value         Mean age, years       0.00 (0.00, 0.01)       0.113       0.00 (-0.00, 0.01)       0.720         Proportion of males, %       0.01 (-0.18, 0.02)       0.891       -0.04 (-0.44, 0.35)       0.828         Definition of short/long sleep       -0.16 (-0.33, 0.10)       0.776       -0.09 (-0.28, 0.10)       0.958         Sample size       -0.09 (-0.18, 0.00)       0.056       -0.08 (-0.25, 0.08)       0.318	Definition of short/long sleep	-0.07 (-0.15, 0.01)	0.099	-0.08 (-0.15, -0.12)	0.011		
Long sleep duration           Univariable analysis         Multivariable analysis           Coef.         P value         Coef.         P value           Mean age, years         0.00 (0.00, 0.01)         0.113         0.00 (-0.00, 0.01)         0.720           Proportion of males, %         0.01 (-0.18, 0.02)         0.891         -0.04 (-0.44, 0.35)         0.828           Definition of short/long sleep         -0.16 (-0.33, 0.10)         0.776         -0.09 (-0.28, 0.10)         0.958           Sample size         -0.09 (-0.18, 0.00)         0.056         -0.08 (-0.25, 0.08)         0.318	Sample size	0.01 (-0.08, 0.09)	0.864	0.01 (-0.09, 0.09)	0.351		
Univariable analysis         Multivariable analysis           Coef.         P value         Coef.         P value           Mean age, years         0.00 (0.00, 0.01)         0.113         0.00 (-0.00, 0.01)         0.720           Proportion of males, %         0.01 (-0.18, 0.02)         0.891         -0.04 (-0.44, 0.35)         0.828           Definition of short/long sleep         -0.16 (-0.33, 0.10)         0.776         -0.09 (-0.28, 0.10)         0.958           Sample size         -0.09 (-0.18, 0.00)         0.056         -0.08 (-0.25, 0.08)         0.318	Study quality	-0.15 (-0.30, 0.00)	0.039	-0.26 (-0.61, 0.09)	0.149		
Coef.P valueCoef.P valueMean age, years0.00 (0.00, 0.01)0.1130.00 (-0.00, 0.01)0.720Proportion of males, %0.01 (-0.18, 0.02)0.891-0.04 (-0.44, 0.35)0.828Definition of short/long sleep-0.16 (-0.33, 0.10)0.776-0.09 (-0.28, 0.10)0.958Sample size-0.09 (-0.18, 0.00)0.056-0.08 (-0.25, 0.08)0.318		Long sleep duration					
Mean age, years0.00 (0.00, 0.01)0.1130.00 (-0.00, 0.01)0.720Proportion of males, %0.01 (-0.18, 0.02)0.891-0.04 (-0.44, 0.35)0.828Definition of short/long sleep-0.16 (-0.33, 0.10)0.776-0.09 (-0.28, 0.10)0.958Sample size-0.09 (-0.18, 0.00)0.056-0.08 (-0.25, 0.08)0.318		Univariable analysis	5	Multivariable analysis			
Proportion of males, %0.01 (-0.18, 0.02)0.891-0.04 (-0.44, 0.35)0.828Definition of short/long sleep-0.16 (-0.33, 0.10)0.776-0.09 (-0.28, 0.10)0.958Sample size-0.09 (-0.18, 0.00)0.056-0.08 (-0.25, 0.08)0.318		Coef.	P value	Coef.	P valu		
Definition of short/long sleep-0.16 (-0.33, 0.10)0.776-0.09 (-0.28, 0.10)0.958Sample size-0.09 (-0.18, 0.00)0.056-0.08 (-0.25, 0.08)0.318	Mean age, years	0.00 (0.00, 0.01)	0.113	0.00 (-0.00, 0.01)	0.720		
Sample size -0.09 (-0.18, 0.00) 0.056 -0.08 (-0.25, 0.08) 0.318	Proportion of males, %	0.01 (-0.18, 0.02)	0.891	-0.04 (-0.44, 0.35)	0.828		
-	Definition of short/long sleep	-0.16 (-0.33, 0.10)	0.776	-0.09 (-0.28, 0.10)	0.958		
Study quality -0.01 (-0.14, 0.10) 0.807 0.01 (-0.50, 0.52) 0.360	Sample size	-0.09 (-0.18, 0.00)	0.056	-0.08 (-0.25, 0.08)	0.318		
	Study quality	-0.01 (-0.14, 0.10)	0.807	0.01 (-0.50, 0.52)	0.360		
	Sample size	-0.09 (-0.18, 0.00)	0.056	-0.08 (-0.25, 0.08)	0.31		

**Figure 1.** Flowchart for the included studies.

#### 354 Figure 2. Forest plot of association between sleep duration and the risk of metabolic syndrome.

355 (A) Comparing short sleepers with normal sleepers; (B) Comparing long sleepers with normal 356 sleepers.

#### 357 Figure 3. Forest plot of association between sleep duration and the prevalence of metabolic

**syndrome.** (A) Comparing short sleepers with normal sleepers; (B) Comparing long sleepers with 359 normal sleepers.

#### **390 12 References**

391 1. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the 392 metabolic syndrome. *Diabetes Care* 2001; **24**(4): 683-9.

2. Daly CA, Hildebrandt P, Bertrand M, et al. Adverse prognosis associated with the metabolic syndrome in established coronary artery disease: data from the EUROPA trial. *Heart* 2007; **93**(11): 1406-11.

395 3. Aguilar M, Bhuket T, Torres S, Liu B, Wong RJ. Prevalence of the metabolic syndrome in the United 396 States, 2003-2012. *JAMA* 2015; **313**(19): 1973-4.

397 4. Di Marzo V, Silvestri C. Lifestyle and Metabolic Syndrome: Contribution of the Endocannabinoidome.
 398 *Nutrients* 2019; **11**(8).

5. Krittanawong C, Tunhasiriwet A, Wang Z, et al. Association between short and long sleep durations and cardiovascular outcomes: a systematic review and meta-analysis. *Eur Heart J Acute Cardiovasc Care* 2019; **8**(8): 762-70.

402 6. Jike M, Itani O, Watanabe N, Buysse DJ, Kaneita Y. Long sleep duration and health outcomes: A
403 systematic review, meta-analysis and meta-regression. *Sleep Med Rev* 2018; **39**: 25-36.

404 7. Ju SY, Choi WS. Sleep duration and metabolic syndrome in adult populations: a meta-analysis of 405 observational studies. *Nutr Diabetes* 2013; **3**: e65.

406 8. Iftikhar IH, Donley MA, Mindel J, Pleister A, Soriano S, Magalang UJ. Sleep Duration and Metabolic
407 Syndrome. An Updated Dose-Risk Metaanalysis. *Ann Am Thorac Soc* 2015; **12**(9): 1364-72.

408 9. XI B. Short sleep duration predicts risk of metabolic syndrome: A systematic review and meta-analysis.
409 2014.

410 10. Karen Grace-Martin AG. Cohort and Case-Control Studies: Pro's and Con's. 2017; 411 https://www.theanalysisfactor.com/cohort-and-case-control-studies-pros-and-cons/.

412 11. Setia MS. Methodology Series Module 3: Cross-sectional Studies. *Indian J Dermatol* 2016; 61(3): 261413 4.

414 12. Deng HB, Tam T, Zee BC, et al. Short Sleep Duration Increases Metabolic Impact in Healthy Adults: A
 415 Population-Based Cohort Study. *Sleep* 2017; **40**(10).

416 13. Grant RL. Converting an odds ratio to a range of plausible relative risks for better communication of 417 research findings. *BMJ* 2014; **348**: f7450.

418 14. Adenekan B, Pandey A, McKenzie S, Zizi F, Casimir GJ, Jean-Louis G. Sleep in America: role of 419 racial/ethnic differences. *Sleep Med Rev* 2013; **17**(4): 255-62.

420 15. Wells G SB, O'Connell D, Peterson J, Welch V, Losos M. The Newcastle-Ottawa Scale (NOS) for
421 assessing the quality of nonrandomised studies in meta-analyses. 2014;
422 http://www.ohri.ca/programs/clinical\_epidemiology/oxford.asp.


423 16. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ*424 2003; **327**(7414): 557-60.

425 17. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, 426 graphical test. *BMJ* 1997; **315**(7109): 629-34.


427 18. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias.

- 428 *Biometrics* 1994; **50**(4): 1088-101.
- 429 19. Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for 430 publication bias in meta-analysis. *Biometrics* 2000; **56**(2); 455-63.
- 431 20. W. V. Conducting meta-analyses in R with the metafor package. *J Stat Softw* 2010; **2010**; **36**: **1–48**.
- 43221.Zhang Tiansong ZS. How to compare summary estimates of different subgroups in meta-analysis.433ChineseJournalofEvidence-BasedMedicine2017;
- 434 https://www.ixueshu.com/document/be6c862ae782c141182f500f64e4272a318947a18e7f9386.html.
- 435 22. Smiley A, King D, Bidulescu A. The Association between Sleep Duration and Metabolic Syndrome:
  436 The NHANES 2013/2014. *Nutrients* 2019; **11**(11).
- 437 23. Spiegel K, Leproult R, Van Cauter E. Impact of sleep debt on metabolic and endocrine function.
  438 Lancet 1999; **354**(9188): 1435-9.
- 439 24. Zimberg IZ, Damaso A, Del Re M, et al. Short sleep duration and obesity: mechanisms and future 440 perspectives. *Cell Biochem Funct* 2012; **30**(6): 524-9.
- 441 25. Meier-Ewert HK, Ridker Pm Fau Rifai N, Rifai N Fau Regan MM, et al. Effect of sleep loss on C-
- 442 reactive protein, an inflammatory marker of cardiovascular risk. 2004
- 443 ; (0735-1097 (Print)).
- Grandner MA, Drummond SP. Who are the long sleepers? Towards an understanding of the mortality
  relationship. *Sleep Med Rev* 2007; **11**(5): 341-60.
- 446 27. Stranges S, Dorn JM, Shipley MJ, et al. Correlates of short and long sleep duration: a cross-cultural
- 447 comparison between the United Kingdom and the United States: the Whitehall II Study and the Western New
- 448 York Health Study. *Am J Epidemiol* 2008; **168**(12): 1353-64.
- 449 28. Allebrandt KV, Teder-Laving M, Akyol M, et al. CLOCK gene variants associate with sleep duration in
  450 two independent populations. *Biol Psychiatry* 2010; **67**(11): 1040-7.
- 451 29. Lemmer B, Oster H. The Role of Circadian Rhythms in the Hypertension of Diabetes Mellitus and the 452 Metabolic Syndrome. *Curr Hypertens Rep* 2018; **20**(5): 43.
- 453 30. Kraemer HC, Kazdin AE, Offord DR, Kessler RC, Jensen PS, Kupfer DJ. Coming to terms with the 454 terms of risk. *Arch Gen Psychiatry* 1997; **54**(4): 337-43.
- 455 31. Buysse DJ. Sleep health: can we define it? Does it matter? *Sleep* 2014; **37**(1): 9-17.
- 456 32. Choi JK, Kim MY, Kim JK, et al. Association between short sleep duration and high incidence of 457 metabolic syndrome in midlife women. *Tohoku J Exp Med* 2011; **225**(3): 187-93.
- 458 33. Otsuka T, Kawada T, Yanai M, Kitagawa Y, Kan H. [Incidence of metabolic syndrome and associated
  459 lifestyle factors in a worksite male population]. *Sangyo Eiseigaku Zasshi* 2011; **53**(3): 78-86.
- 460 34. Chaput JP, McNeil J, Despres JP, Bouchard C, Tremblay A. Short sleep duration as a risk factor for 461 the development of the metabolic syndrome in adults. *Prev Med* 2013; **57**(6): 872-7.
- 462 35. Kim JY, Yadav D, Ahn SV, et al. A prospective study of total sleep duration and incident metabolic 463 syndrome: the ARIRANG study. *Sleep Med* 2015; **16**(12): 1511-5.
- 464 36. Li X, Lin L, Lv L, et al. U-shaped relationships between sleep duration and metabolic syndrome and 465 metabolic syndrome components in males: a prospective cohort study. *Sleep Med* 2015; **16**(8): 949-54.

- 466 37. Song Q, Liu X, Zhou W, Wang X, Wu S. Changes in sleep duration and risk of metabolic syndrome:
- the Kailuan prospective study. *Sci Rep* 2016; **6**: 36861.
- 468 38. Itani O, Kaneita Y, Tokiya M, et al. Short sleep duration, shift work, and actual days taken off work are
- 469 predictive life-style risk factors for new-onset metabolic syndrome: a seven-year cohort study of 40,000 male
- 470 workers. *Sleep Med* 2017; **39**: 87-94.
- 471 39. Ye Y, Zhang L, Wang A, et al. Association of sleep duration with stroke, myocardial infarction, and
- 472 tumors in a Chinese population with metabolic syndrome: a retrospective study. *Lipids Health Dis* 2020; **19**(1):
- 473 155.



% Weight




→ 1.57 (0.61, 4.01) Choi JK men (2011) 0.93 1.66 (0.71, 3.88) Choi JK women (2011) 1.07 Chaput J. (2013) 1.13 (0.58, 1.98) 4.90 Kim J.Y. (2015) 0.73 (0.45, 1.13) 14.55 ➡ 1.96 (1.35, 2.85) Li X. men (2015) 4.34 Li X. women (2015) 0.93 (0.60, 1.53) Song Q. (2016) 1.24 (0.93, 1.66) 13.32 Deng H.B. (2017) 0.93 (0.88, 0.99) 35.75 Yingtan Y.E. (2020) 0.96 (0.69, 1.33) 15.64 Overall (I-squared = 38.0%, p = 0.115) 1.02 (0.85, 1.18) 100.00 NOTE: Weights are from random effects analysis

ID



% Weight



Santas A.C. men (2007) Santas A.C. women (2007) Choi KM (2008) Hall MH (2008) Aroar T (2011) Kobavashi D. (2011) Najafian J. (2011) Sabanayagam C. (2012) Wu M, men (2012) Wu M. women (2012) Hung H.C. (2013) Yoo H. (2013) Saleh D. (2014) Yu S. men (2014) Yu S. women (2014) Chang J.H. men (2015) Wu J, men (2015) Wu J. women (2015) Lin S.C. (2016) Min H. women (2016) Xiao J. men (2016) Xiao J. women (2016) Cole H.V. (2017) Suliga E. men (2017) Suliga E. women (2017) Kaira C. (2018) Kim C.E. men (2018) Kim C.E. women (2018) Ostadrahimi A. (2018) Titova O.G. (2018) Qian Y.X. (2019) Overall (I-squared = 73.8%, p = 0.000) NOTE: Weights are from random effects analysis 5

